Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic skin disorder characterized by fragile skin that leads to chronic, difficult-to-treat wounds. Researchers have been exploring new therapeutic approaches to improve wound healing and quality of life in individuals with RDEB. As part of these efforts, a phase 3 clinical trial evaluated the efficacy and safety of an autologous gene-modified skin graft, prademagene zamikeracel, in 11 patients with RDEB.
The study found that at week 24, 81% of wounds treated with prademagene zamikeracel were at least 50% healed from baseline, compared to 16% of control wounds (mean difference: 67%). The mean change in wound pain was –3.07 with prademagene zamikeracel versus –0.90 in controls, with no serious treatment-related adverse events observed. These findings suggest that prademagene zamikeracel significantly enhances wound healing and…
